PharmaFocus Today – Page 4 – media

Dongbao Pharmaceutical’s human insulin raw materials have been approved for entry into the Pakistani market

According to Tonghua Dongbao, the company’s human insulin raw material product recently received approval from the National Drug Regulatory Authority of Pakistan, marking a new step forward in its internationalization strategy as the product can now be officially supplied to the Pakistani market. This approval was achieved by the company, as a supplier of human insulin raw materials, by supporting overseas clients in completing the registration and market approval of their formulation products in Pakistan, demonstrating the overseas competitiveness of the company’s raw material products. With over two decades of experience in the insulin field, the company has built a mature and stable large-scale raw material production system and a full life-cycle quality control system, enabling it to provide reliable and continuous raw material supplies to its global partners. Pakistan bears one of the heaviest burdens of diabetes globally. Data from the International Diabetes Federation shows that in 2024, Pakistan ...
- Source: drugdu
- 50
- April 27, 2026
Smegglutide begins to fight back

GLP-1 drugs have rapidly become a core segment of the global pharmaceutical market in the past two years. For a long time, the competitive logic of these drugs was highly simplified to a single indicator: the rate of weight loss . Temerpotide, with its higher average weight loss rate demonstrated in clinical trials, has gained a significant cognitive advantage, while its pioneering drug, semaglutide, has gradually been surpassed in this dimension, allowing temerpotide to benefit from its late-mover advantage. This weight-centric assessment method has a natural advantage in terms of dissemination. Weight loss is an intuitive, quantifiable, and quickly comparable indicator, and it is also easier for patients and non-professionals to understand. However, the problem is that this indicator itself cannot distinguish the components of weight loss . Fat loss and lean body mass loss are presented together in weight data, but the two have completely different values in a ...
- Source: drugdu
- 51
- April 27, 2026
Johnson & Johnson’s “Twin Stars” of Immunization Rise

Johnson & Johnson recently released its financial results for the first quarter of 2026. In terms of overall performance, the company achieved sales of US$24.06 billion during the reporting period, representing a year-on-year increase of 9.9%. Johnson & Johnson also raised its full-year guidance: it expects full-year sales in 2026 to reach US$100.3 billion to US$101.3 billion , with a median growth rate of 7.0%. Of these, global revenue from innovative pharmaceuticals grew by 11% to $15.4 billion. Oncology remained the mainstay of performance, with revenue of $6.97 billion, a significant year-on-year increase of 22.8%. However, the immunology business is entering a period of adjustment , with revenue of $3.38 billion, a year-on-year decrease of 8.8%. Stelara, the immunology powerhouse with annual sales of tens of billions of dollars, is shrinking rapidly due to the impact of biosimilars, while Tremfya and Icotyde are emerging as new hope. 01 The Rise ...
- Source: drugdu
- 51
- April 27, 2026
Guang Sheng Tang-Neraprazole initiated a Phase I clinical trial in China for liver injury and chronic hepatitis B.

On April 23, 2026, Guang Sheng Tang initiated a Phase I clinical trial in China for nerecvir (an HBcAg inhibitor) for the indication of liver injury and chronic hepatitis B. The trial (CTR20261605), titled “Pharmacokinetics and Safety Study of GST-HG141 Tablets in Participants with Impaired and Normal Liver Function,” plans to enroll 24 subjects. The investigational drug in this clinical trial is Neratrovir. The primary endpoints include the following pharmacokinetic parameters: Cmax (maximum plasma concentration), Tmax (time to peak concentration), t1 /2 (half-life), AUC0 -t (area under the curve from dosing to the last detection time), AUC0 -∞ (area under the curve from dosing to infinity), CL/F (apparent clearance), Vz/F (apparent volume of distribution), and plasma protein binding rate. https://bydrug.pharmcube.com/news/detail/794753dd6168e510cf7df98863df6eea
- Source: drugdu
- 78
- April 24, 2026
the global setbacks of FIC

Once a global FIC drug, it has suffered a major setback in the domestic market. According to the NMPA website, Daiichi Sankyo’s Pexidartinib received a “drug notification.” While the specific reason has not been disclosed, this means the drug has not been approved. Of course, this result is not entirely unexpected. After all, while pexidartinib does offer improved patient benefits, its risks cannot be ignored; it had previously been rejected by the EMA in Europe. Meanwhile, in China, pimitinib, with its superior efficacy and safety profile, has already been approved for marketing. To some extent, the failure of Pexidartinib is not just a failure of a single drug, but also reflects a change in the times. With the continuous rise of domestically developed innovative drugs, offering patients better options, domestic regulatory authorities are imposing increasingly higher requirements on drug review and approval. This is especially true for drugs treating non-fatal ...
- Source: drugdu
- 76
- April 24, 2026
Yingpai Pharmaceutical is about to go public.

On April 20, Yingpai Pharmaceutical’s IPO application on the Hong Kong Stock Exchange passed the hearing, meaning it is about to be listed. Founded in 2009, Imbisoft is dedicated to advancing precision oncology therapies based on synthetic lethal mechanisms globally. Imbisoft has built a robust pipeline in the field of synthetic lethality, and is one of only three companies worldwide to simultaneously possess commercially viable PARP1/2 inhibitors and next-generation PARP1 inhibitors in clinical trials. The pipeline for future research and development includes ATR inhibitors, WEE1 inhibitors, SHX9 inhibitors, brain-penetrating PARP1 inhibitors, ATM inhibitors, USP1 inhibitors, CHK1/2 inhibitors, and more. Yingpai Pharmaceutical’s R&D expenditures in 2024 and 2025 were RMB 195 million and RMB 184 million, respectively. As of the end of 2025, Yingpai Pharmaceutical had RMB 259 million in cash on hand. In conclusion , regarding business development (BD) collaborations, Innovent Biologics licensed the overseas rights to its PARP1 inhibitors ...
- Source: drugdu
- 76
- April 24, 2026
Breaking News! The world’s leading medical device company completes a major acquisition.

Recently, Medtronic, the world’s leading medical device company, announced the completion of its acquisition of CathWorks, significantly increasing its investment in the cardiovascular field. Image source: Medtronic official website 01 Cardiovascular track Continue to increase investment CathWorks, founded in 2013, has focused on developing cardiovascular imaging and treatment solutions based on computer vision and artificial intelligence technologies , aiming to provide objective data for percutaneous coronary intervention (PCI) decisions. It’s worth noting that Medtronic’s acquisition of CathWorks was not accidental, but rather the result of nearly eight years of gradual integration. As early as 2018, Medtronic already held a minority stake in CathWorks; in 2022, the relationship between the two parties was further upgraded to a strategic partnership, at which time Medtronic invested approximately US$75 million to jointly promote CathWorks’ core product, the FFRangio system, in the US, European, and Japanese markets . On February 3, 2026, Medtronic officially announced ...
- Source: drugdu
- 75
- April 24, 2026
Maiwei Biotech adds another potential drug

Currently, 12 TCE drugs have been approved for marketing globally, 9 of which are used to treat hematological malignancies, targeting tumor antigens such as CD20, BCMA, CD19, and GPRC5D. Meanwhile, a number of emerging targets are beginning to appear in the pipeline. Recently, Maiwei Bio announced that the NMPA has accepted its clinical trial application for its independently developed 6MW5311, which is intended to be developed for hematological malignancies (acute myeloid leukemia, chronic myelomonocytic leukemia and multiple myeloma). It is worth noting that 6MW5311 is the world’s first innovative bispecific antibody targeting LILRB4/CD3 TCE to be submitted for clinical trials. Its application for clinical trials in the United States is already in the pre-IND stage, and the company plans to formally submit the application to the FDA in the second quarter of 2026. 01 Differentiation targeting the “drug shortage” market LILRB4 (a member of the leukocyte immunoglobulin-like receptor subfamily B) ...
- Source: drugdu
- 69
- April 24, 2026
The Hidden Champion in the Chronic Disease Market

Recently, Kanghong Pharmaceutical released its 2025 annual report, showing annual revenue of 4.585 billion yuan, a year-on-year increase of 2.98%, and net cash flow from operating activities of 1.504 billion yuan, a year-on-year increase of 6.50%. This marks the fifth consecutive year of steady growth. In an industry context where innovative drugs face a high risk of failure and centralized procurement has become the norm, where does Kanghong Pharmaceutical’s growth resilience come from? The answer lies not only in its impressive surge in biopharmaceuticals, but also in its long-term, meticulous cultivation of traditional Chinese medicine. Data shows that the company’s traditional Chinese medicine segment achieved revenue of 1.496 billion yuan, a year-on-year increase of 5.80% , leading the overall growth rate. While the market chases one hot biopharmaceutical trend after another, it has quietly built an insurmountable moat in the field of traditional Chinese medicine. Focusing on the golden track ...
- Source: drugdu
- 57
- April 24, 2026
GSK announces that belantamab mafodotin has been approved in China.

On April 20, 2026 , GlaxoSmithKline (GSK) announced that its drug Blenrep (generic name: belantamab mafodotin) had been approved by the National Medical Products Administration (NMPA) of China. The approved indication is for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) in combination with bortezomib and dexamethasone (BVd regimen) who have received at least one prior line of therapy . This approval was based on the priority review process, and the combination therapy had previously been granted Breakthrough Therapy designation in China, both because it is expected to provide significant improvements over existing therapies. Core approval information and key data Approved regimen : Blenrep + bortezomib + dexamethasone (BVd). Target patients : Adult patients with relapsed or refractory multiple myeloma who have previously received at least one first-line treatment. Key advantages : 1) It is the first and only approved anti-BCMA (B-cell maturation antigen) therapy in ...
- Source: drugdu
- 78
- April 23, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.